Topics

MSD and 4D Pharma Collaborate to Develop Live Biotherapeutics for Vaccines

14:04 EDT 8 Oct 2019 | Speciality Pharma Journal

LEEDS, England, Oct. 8, 2019 /PRNewswire/ — 4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutics, today announces that the Company has entered into a research collaboration and option to license agreement with MSD, the tradename of Merck & Co., Inc., Kenilworth, NJ, USA, to discover and develop Live Biotherapeutics …

Original Article: MSD and 4D Pharma Collaborate to Develop Live Biotherapeutics for Vaccines

NEXT ARTICLE

More From BioPortfolio on "MSD and 4D Pharma Collaborate to Develop Live Biotherapeutics for Vaccines"

Quick Search

Relevant Topics

Biotherapeutics
The field encompassing therapeutic materials produced using biological means, including recombinant DNA technology. Biotherapeutics, also known as biotech drugs or biologics, are therapies derived from living organisms. By harnessing these living cells...

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...